GMP Manufacturing Base
- 1600 m² GMP manufacturing base with clinical-scale manufacturing capacity
Complete, Efficient and Stable Manufacturing Capacity and Quality Control
- An enlarged and stable manufacturing process in order to keep important parameters stable in the whole process
- The gene editing efficiency with guaranteed efficacy and safety
Poster Presentation at the 61st ASH Annual Meeting
In December 2019, at the 61st ASH Annual Meeting, presented preclinical data on ET-01, its leading therapeutic program for patients with β-Thalassemia Major, during the 61st American Society of Hematology (ASH) Annual Meeting.
The presentation highlighted selected data from scaled-up manufacturing campaigns at clinical scale and IND-enabling preclinical studies of ET-01.